Alprazolam is a small molecule commercialized by UCB, with a leading Phase III program in Seizures. According to Globaldata, it is involved in 8 clinical trials, of which 6 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Alprazolam’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Alprazolam is expected to reach an annual total of $133 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Alprazolam (AZ-002) is under development for the treatment of seizures and epilepsy. The drug candidate is administered through inhalational route. It is combination of proprietary staccato system with alprazolam. The drug candidate was also under development for the treatment of acute panic attacks.
UCB is a biopharmaceutical company that is engaged in the discovery and development of novel medicines and solutions for the treatment of various severe diseases. It strives to develop products for the treatment of neurology and immunology related conditions. The company’s marketed products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn’s disease, psoriatic arthritis, non-radiographic axial spondyloarthritis and rheumatoid arthritis; Neupro for Parkinson’s disease and restless legs syndrome; Evenity for osteoporosis, and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Brussels-Capital Region, Belgium.
The company reported revenues of (Euro) EUR5,777 million for the fiscal year ended December 2021 (FY2021), an increase of 8% over FY2020. In FY2021, the company’s operating margin was 22.2%, compared to an operating margin of 18.2% in FY2020. In FY2021, the company recorded a net margin of 18.3%, compared to a net margin of 13.7% in FY2020.
For a complete picture of Alprazolam’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.